Calcitonin (Salmon)

Calcitonin is a 32-amino-acid peptide hormone physiologically secreted by the parafollicular (C) cells of the thyroid in response to rising serum calcium. It binds the calcitonin receptor, a G-protein-coupled receptor, most abundantly on osteoclasts, where it inhibits osteoclast-mediated bone resorption, reducing the release of calcium and phosphate from bone; it also promotes renal calcium excretion. The net effect is a lowering of serum calcium. The salmon-derived form used clinically is roughly 40-50 times more potent than human calcitonin and has a longer duration of action because of higher receptor affinity and slower degradation, which is why salmon calcitonin — not the human sequence — is the therapeutic agent. Analgesic effects reported in some conditions (e.g., acute vertebral fracture, Paget's disease) may involve central mechanisms that are not fully characterized.

Salmon calcitonin is a well-characterized, approved medicine with decades of human clinical data across hypercalcemia, Paget's disease, and (historically) postmenopausal osteoporosis. Its long-term safety was re-evaluated after pooled analyses signaled a small excess of malignancies with prolonged use: Overman et al. (2013) reviewed the evidence, and a meta-analysis (Wells et al., Osteoporosis International 2016) examined whether salmon calcitonin causes cancer. On this basis the EMA's 2012 review found the benefit-risk balance unfavorable for osteoporosis and recommended withdrawing the nasal spray for that indication while restricting other uses to short courses.

Educational overview only — no dosing instructions in the public hub.

Pooled trial data suggested a small increase in overall cancer rates with long-term calcitonin use (on the order of 0.7% for oral and ~2.4% for the nasal-spray formulation versus placebo), which drove regulatory restriction of long-term and osteoporosis use. Common adverse effects include nausea, flushing, and injection-site or nasal reactions; the nasal spray can cause rhinitis and epistaxis. Hypersensitivity reactions can occur, and hypocalcemia is possible. It is a prescription-only drug that must be used under medical supervision, at the lowest effective dose for the shortest necessary duration.

Calcitonin is a regulated prescription pharmaceutical; legitimate use means an approved product (e.g., Miacalcin) dispensed by a pharmacy, not 'research-grade' or gray-market peptide of unverified identity and purity. Approved formulations are manufactured under GMP with defined potency and stability. This entry reflects the approved medicine as studied and regulated, not unregulated material sold outside the pharmaceutical supply chain.

Approved prescription medication (FDA and EMA), historically marketed as Miacalcin/Miacalcic and Fortical. Following the EMA's 2012 review, the nasal spray for osteoporosis was withdrawn in the EU and use was restricted to short-term treatment of limited indications (Paget's disease when alternatives are unsuitable, acute immobilization-related bone loss, hypercalcemia of malignancy). Requires a physician's prescription and medical supervision.